ClinicalTrials.gg
Sign In
Status unknownNCT03817177Updated Mar 7, 2019

Application of High Flow Nasal Cannula for Prevention of Post-extubation Atelectasis in Children Undergoing Surgery

An interventional study of high flow nasal cannula oxygenation and nasal prong in Atelectasis, sponsored by Seoul National University Hospital. Status unknown at 1 site in South Korea. Open to participants aged 1 Day to 2 Years. Per ClinicalTrials.gov, last updated 2019-03-07.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Mar 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
1 Day to 2 Years
Sex
All
01

Study summary

postoperative atelectasis observation by ultrasound after application of high flow nasal cannula oxygenation

Read the detailed description

After surgery, postoperative atelectasis observation by ultrasound grading comparison between application of conventional nasal prong and high flow nasal cannula device

02

Conditions studied

  • Atelectasis

Browse trials for

03

In context

Pulmonary Atelectasis

308 studies on the registry are indexed under Pulmonary Atelectasis; 79 are open to participants now.

This study's planned enrollment of 80 is above the median of 61 across 226 interventional studies indexed under Pulmonary Atelectasis.

Browse Pulmonary Atelectasis studies →

Lead sponsor

Seoul National University Hospital is the lead sponsor of 1,897 studies on the registry; 273 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Browse Seoul National University Hospital studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 2 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • general anesthesia

Exclusion criteria

Exclusion Criteria:

  • preterm
  • bronchopulmonary dysplasia
  • upper respiratory infection history
  • respiratory disease
  • cardiac surgery
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Placebo comparator
    nasal prong

    conventional nasal prong application after the surgery in postanesthetic care unit (PACU)

    Procedure: nasal prong

  • Experimental
    high flow nasal cannula oxygenation

    high flow nasal cannula application after the surgery in postanesthetic care unit (PACU)

    Procedure: high flow nasal cannula oxygenation

Interventions

  • Procedurehigh flow nasal cannula oxygenation

    high flow nasal cannula application in PACU

  • Procedurenasal prong

    conventional nasal prong application in PACU

06

What researchers measure

Primary outcomes

  1. lung sound score

    0: Normal aeration (N): presence of lung sliding with A lines or fewer than two isolated B lines 1. Moderate loss of lung aeration: multiple well-defined B lines (B1 lines) 2. Severe loss of lung aeration: multiple coalescent B lines (B2 lines) 3. Lung consolidation (C): the presence of a tissue pattern characterized by dynamic air

    Time frame: 30 minutes after arrival of postanesthetic care unit

07

Study locations

1 of 1 sites recruiting
  • Seoul National University Hospital
    Seoul, South Korea
    • Heesoo Kim · Contact
    Recruiting
08

References and documents

Publications

  • Lee JH, Ji SH, Jang YE, Kim EH, Kim JT, Kim HS. Application of a High-Flow Nasal Cannula for Prevention of Postextubation Atelectasis in Children Undergoing Surgery: A Randomized Controlled Trial. Anesth Analg. 2021 Aug 1;133(2):474-482. doi: 10.1213/ANE.0000000000005285. PubMed 33181560 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2019 (actual). Primary completion is estimated for Jan 2021, 22 months after the start.

Of 133 non-industry interventional studies with no phase under Pulmonary Atelectasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 25. This study's planned 22 months is above that.

Counting every sponsor, half of 135 studies reached it within 12 months; a quarter within 6 and three quarters within 25.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2019
First posted
Jan 25, 2019
StartActual
Mar 2, 2019
Primary completionEst.
Jan 30, 2021
CompletionEst.
Jun 30, 2021
Last update
Mar 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03817177
Lead sponsor
Seoul National University Hospital
Responsible party
Hee-Soo Kim (principle investigator, Seoul National University Hospital) — Principal investigator
First posted
Jan 25, 2019
Start date
Mar 2, 2019
Primary completion
Jan 30, 2021 (estimated)
Completion
Jun 30, 2021 (estimated)
Last update
Mar 7, 2019

Study contacts

Hee-Soo Kim, MD, Phd
Contact
dami0605@snu.ac.kr
0220723659
Ji-Hyun Lee, MD, PHd
Contact
0220723664
Hee-Soo Kim
principal investigator · Seoul National University Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Pulmonary Atelectasis →

Other studies from this sponsor

Seoul National University Hospital →

Start the discussion